Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sikokianin C is a natural biflavonoid compound isolated from the medicinal herb Stellera chamaejasme. It functions as a selective, competitive inhibitor of cystathionine β-synthase (CBS), an enzyme involved in the transsulfuration pathway and linked to cancer cell proliferation and migration, particularly in colon cancer. Sikokianin C significantly inhibits the proliferation and induces apoptosis of human colon cancer cells (e.g., HT29) in vitro, and reduces tumor growth in mouse xenograft models. Its mechanism involves binding to the substrate channel of CBS, with five key residues identified for this interaction. Unlike the commonly used CBS inhibitor AOAA, sikokianin C does not inhibit cystathionine γ-lyase (CSE), making it a more selective tool for studying CBS-related pathways. It also demonstrates antimalarial activity against chloroquine-resistant Plasmodium falciparum[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sikokianin C.